Fig. 2

Estimated EQ-5D mean utility values by MMD frequency for erenumab and placebo, mapped from HIT-6. Abbreviations: CI confidence interval, EQ-5D 5-dimension EuroQol questionnaire, HIT-6 Headache Impact Test, MMD monthly migraine day, REML restricted maximum likelihood. Observed values with 95% CIs are represented by blue, green and red vertical lines for erenumab 140 mg and 70 mg and placebo, respectively. (a) Linear mixed effects model with REML (b) Fractional response model with logit link, (c) Fractional response model with probit link and (d) beta regression model